← Elanco Animal Health Inc
| Annual Trend | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Depreciation and amortization | $318.4m | $296.0m | $314.5m | $516.9m | $716.0m | $682.0m | $694.0m | $662.0m | $680.0m | $693.0m | |
| Deferred income taxes | ($13.4m) | ($60.7m) | $100k | ($124.8m) | ($154.0m) | ($57.0m) | ($80.0m) | ($112.0m) | ($134.0m) | ($134.0m) | |
| Stock-based compensation expense | $25.0m | $26.0m | $49.4m | $47.7m | $66.0m | $59.0m | $46.0m | $55.0m | $68.0m | $74.0m | |
| Goodwill impairment | — | — | — | — | $0 | $0 | $1.0b | $0 | $0 | $20.0m | |
| Asset impairment and write-down charges | $110.6m | $120.5m | $32.6m | $25.1m | $339.0m | $81.0m | $32.0m | $81.0m | $71.0m | — | |
| Receivables | $48.4m | ($122.0m) | ($172.4m) | $14.0m | ($25.0m) | $14.0m | ($40.0m) | $12.0m | ($12.0m) | ($12.0m) | |
| Inventories | ($39.0m) | ($20.1m) | ($33.1m) | ($94.7m) | $27.0m | ($269.0m) | ($160.0m) | $44.0m | ($57.0m) | ($57.0m) | |
| Accounts payable and other liabilities | ($8.4m) | $116.1m | ($29.2m) | $369.3m | ($120.0m) | ($98.0m) | ($94.0m) | $82.0m | $147.0m | $147.0m | |
| Other assets | $52.5m | ($3.2m) | $7.0m | ($122.9m) | $22.0m | ($109.0m) | ($6.0m) | $11.0m | $21.0m | — | |
| Net Cash Provided by Operating Activities | $173.8m |
$487.3m
+180.38%
|
$224.1m
-54.01%
|
($41.0m)
-118.30%
|
$483.0m
+1278.05%
|
$452.0m
-6.42%
|
$271.0m
-40.04%
|
$541.0m
+99.63%
|
$560.0m
+3.51%
|
$617.0m
+10.18%
|
|
| Net purchases of property and equipment and software | ($98.6m) | ($134.5m) | ($140.4m) | ($134.6m) | ($126.0m) | ($137.0m) | ($140.0m) | ($147.0m) | ($276.0m) | — | |
| Gain on divestiture | — | $0 | $0 | ($170.0m) | $1.0m | ($3.0m) | $0 | ($640.0m) | $0 | — | |
| Cash paid for acquisitions | ($882.1m) | $0 | ($32.8m) | ($5.0b) | ($342.0m) | $0 | ($19.0m) | ($41.0m) | $0 | — | |
| Proceeds from divestitures | — | — | — | — | — | $0 | $0 | $1.3b | $9.0m | — | |
| Other investing activities, net | ($3.0m) | $100k | ($4.9m) | ($7.1m) | ($8.0m) | ($8.0m) | $4.0m | $0 | ($12.0m) | — | |
| Net Cash (Used for) Provided by Investing Activities | ($964.6m) | ($127.0m) | ($234.8m) | ($4.8b) | ($530.0m) | ($179.0m) | ($169.0m) | $1.2b | ($279.0m) | — | |
| Proceeds from issuance of long-term debt | $0 | $2.5b | $0 | $4.8b | $500.0m | $425.0m | $0 | $350.0m | $2.1b | $2.2b | |
| Repayments of long-term borrowings | $0 | ($7.5m) | ($121.1m) | ($951.5m) | ($573.0m) | ($677.0m) | ($402.0m) | ($1.6b) | ($2.7b) | — | |
| Other financing activities, net | ($800k) | ($17.2m) | $1.6m | ($16.2m) | ($29.0m) | ($16.0m) | ($6.0m) | ($17.0m) | ($2.0m) | — | |
| Net Cash Used for Financing Activities | $847.5m |
($35.2m)
-104.15%
|
($304.8m)
-765.91%
|
$5.0b
+1725.30%
|
$210.0m
-95.76%
|
($549.0m)
-361.43%
|
($83.0m)
+84.88%
|
($1.5b)
-1697.59%
|
($275.0m)
+81.57%
|
— | |
| Effect of exchange rate changes on cash and cash equivalents | $7.9m | $29.0m | ($16.9m) | $26.6m | ($31.0m) | ($17.0m) | ($12.0m) | ($91.0m) | $71.0m | $19.0m | |
| Additional Supplementary Disclosures | |||||||||||
| Additional Supplementary Disclosures | |||||||||||
| Net (loss) income | ($310.7m) | $86.5m | $67.9m | ($560.1m) | ($472.0m) | ($78.0m) | ($1.2b) | $338.0m | ($232.0m) | — | |
| Proceeds from interest rate swap settlements | — | — | — | $0 | $0 | $207.0m | $57.0m | $5.0m | $0 | — | |
| Sold portion of royalty revenue | — | — | — | — | — | — | $0 | $0 | ($19.0m) | — | |
| Interest on liability for sale of future revenue | — | — | — | — | — | — | $0 | $0 | $33.0m | — | |
| Other non-cash operating activities, net | $10.0m | $49.0m | ($12.7m) | $19.7m | $6.0m | ($2.0m) | $9.0m | $3.0m | ($6.0m) | — | |
| Proceeds from facility | — | — | $0 | $0 | $500.0m | $563.0m | $600.0m | $220.0m | $250.0m | — | |
| Repayments of facility | — | — | $0 | $0 | ($250.0m) | ($813.0m) | ($275.0m) | ($445.0m) | ($250.0m) | — | |
| Proceeds from sale of future revenue, net of transaction costs | — | — | — | — | — | — | $0 | $0 | $290.0m | — | |
| Net increase in cash and cash equivalents | $64.6m | $354.1m | ($332.4m) | $160.3m | $132.0m | ($293.0m) | $7.0m | $116.0m | $77.0m | — | |
| Cash and cash equivalents at January 1 | $323.4m | $677.5m | $345.1m | $505.4m | $638.0m | $345.0m | $352.0m | $468.0m | $545.0m | — |
Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.